1. 2643 Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (UBC): Updated clinical and translational findings of an open-label, single group, phase 2 study. (September 2015) Authors: Necchi, A.; Giannatempo, P.; Mariani, L.; Raggi, D.; Nicolai, N.; Piva, L.; Biasoni, D.; Catanzaro, M.; Torelli, T.; Stagni, S.; Calareso, G.; Togliardi, E.; Colecchia, M.; Busico, A.; Perrone, F.; Pelosi, G.; Maffezzini, M.; Salvioni, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S528 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗